305371-42-0

Basic information

• Product Name: Methyl 5-(Boc-aMino)-2-ch...
• Synonyms: Methyl 5-(Boc-aMino)-2-ch...;Methyl 5-(Boc-aMino)-2-chloropyridine-4-carboxylate;methyl 5-{[(tert-butoxy)carbonyl]amino}-2-chloropyridine-4-carboxylate;Methyl 5-((tert-butoxycarbonyl)amino)-2-chloroisonicotinate
• CAS NO: 305371-42-0
• Molecular Formula: C₁₂H₁₅ClN₂O₄
• Molecular Weight: 286.72
• Mol File: 305371-42-0.mol

Chemical Properties

• Boiling Point: 357.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.294±0.06 g/cm3(Predicted)
• PKA: 11.45±0.70(Predicted)
• CAS DataBase Reference: Methyl 5-(Boc-aMino)-2-ch...(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-(Boc-aMino)-2-ch...(305371-42-0)
• EPA Substance Registry System: Methyl 5-(Boc-aMino)-2-ch...(305371-42-0)

Safety Data

• Hazardous Substances Data: 305371-42-0(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
Methyl 5-(Boc-amino)-2-chloronicotinate is used as a building block for the synthesis of various organic compounds, contributing to the advancement of chemical research.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Methyl 5-(Boc-amino)-2-chloronicotinate is used as a key intermediate in the development of new drugs or biologically active molecules, owing to its unique structural features and the protective role of the Boc group in amine functional groups.
Used in Drug Development:
Methyl 5-(Boc-amino)-2-chloronicotinate is employed in drug development for its potential to contribute to the creation of novel therapeutic agents, particularly due to the presence of the 2-chloronicotinate moiety, which may offer unique pharmacological properties.

Upstream product

• 171178-46-4 5-[N-(tert-butoxycarbonyl)amino]-2-chloropyridine-4-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-56-1 methanol 
• 5350-93-6 6-Chloro-pyridin-3-ylamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 171178-45-3 tert-butyl (6-chloropyridin-3-yl)carbamate 

Downstream Products

• 305371-16-8 [6-fluoro-4-(3-nitrilo-propionyl)-pyridin-3-yl]-carbamic acid, tert-butyl ester 
• 668434-68-2 methyl 5-{(tert-butoxy)-N-[(4-methoxyphenyl)methyl]carbonylamino}-2-chloropyridine-4-carboxylate 
• 1073182-59-8 methyl 5-amino-2-chloroisonicotinate 

Relevant articles and documents

PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS

The invention relates to compounds of formula (I) or pharmaceutically acceptable salts or solvates thereof, to pharmaceutical compositions comprising them and to their use in the treatment and/or prevention of diseases or disorders mediated by histamine H4 receptor.

Combination therapy with CHK1 inhibitors

Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents.

Inhibition of FGFR3 and treatment of multiple myeloma

Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.

SUBSTITUTED-3-CYANO-[1.7],[1.5], AND [1.8]-NAPHTHYRIDINE INHIBITORS OF TYROSINE KINASES

This invention provides compounds of formula (I) having structure (a) wherein A'' is a diavalent moiety selected from the group (a, b, c) which are useful as inhibitors of protein tyrosine kinase.

BENZIMIDAZOLE QUINOLINONES AND USES THEREOF

Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.